Fulgent Genetics annual gross margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fulgent Genetics's gross margin was 40.56% for fiscal 2025.
View full Fulgent Genetics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 40.56% | +2.74 pp |
| 2024 | 2024-12-31 | 37.82% | +1.71 pp |
| 2023 | 2023-12-31 | 36.12% | −23.16 pp |
| 2022 | 2022-12-31 | 59.28% | −19.01 pp |
| 2021 | 2021-12-31 | 78.29% | −0.42 pp |
| 2020 | 2020-12-31 | 78.70% | +22.07 pp |
| 2019 | 2019-12-31 | 56.63% | +6.73 pp |
| 2018 | 2018-12-31 | 49.90% | −4.45 pp |
| 2017 | 2017-12-31 | 54.35% | −8.87 pp |
| 2016 | 2016-12-31 | 63.22% | +16.15 pp |
| 2015 | 2015-12-31 | 47.07% | +20.31 pp |
| 2014 | 2014-12-31 | 26.76% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 30.07% | −12.02 pp |
| Q1 2026 | 2026-03-31 | 30.21% | −8.38 pp |
| Q4 2025 | 2025-12-31 | 39.10% | −2.69 pp |
| Q3 2025 | 2025-09-30 | 42.24% | +4.93 pp |
| Q2 2025 | 2025-06-30 | 42.10% | +4.80 pp |
| Q1 2025 | 2025-03-31 | 38.59% | +4.31 pp |
| Q4 2024 | 2024-12-31 | 41.79% | +6.01 pp |
| Q3 2024 | 2024-09-30 | 37.32% | −9.73 pp |
| Q2 2024 | 2024-06-30 | 37.30% | +6.98 pp |
| Q1 2024 | 2024-03-31 | 34.28% | +5.85 pp |
| Q4 2023 | 2023-12-31 | 35.78% | +16.60 pp |
| Q3 2023 | 2023-09-30 | 47.05% | +3.42 pp |
| Q2 2023 | 2023-06-30 | 30.32% | −21.76 pp |
| Q1 2023 | 2023-03-31 | 28.43% | −47.30 pp |
| Q4 2022 | 2022-12-31 | 19.18% | −56.13 pp |
| Q3 2022 | 2022-09-30 | 43.63% | −37.30 pp |
| Q2 2022 | 2022-06-30 | 52.08% | −24.58 pp |
| Q1 2022 | 2022-03-31 | 75.73% | −3.66 pp |
| Q4 2021 | 2021-12-31 | 75.31% | −7.14 pp |
| Q3 2021 | 2021-09-30 | 80.92% | +6.74 pp |
| Q2 2021 | 2021-06-30 | 76.66% | +21.35 pp |
| Q1 2021 | 2021-03-31 | 79.39% | +31.72 pp |
| Q4 2020 | 2020-12-31 | 82.45% | +25.78 pp |
| Q3 2020 | 2020-09-30 | 74.18% | +11.73 pp |
| Q2 2020 | 2020-06-30 | 55.30% | −1.72 pp |
| Q1 2020 | 2020-03-31 | 47.67% | +2.94 pp |
| Q4 2019 | 2019-12-31 | 56.67% | +5.48 pp |
| Q3 2019 | 2019-09-30 | 62.45% | +8.89 pp |
| Q2 2019 | 2019-06-30 | 57.03% | +4.14 pp |
| Q1 2019 | 2019-03-31 | 44.73% | +4.30 pp |
| Q4 2018 | 2018-12-31 | 51.19% | +10.64 pp |
| Q3 2018 | 2018-09-30 | 53.56% | +3.93 pp |
| Q2 2018 | 2018-06-30 | 52.89% | −6.62 pp |
| Q1 2018 | 2018-03-31 | 40.43% | −24.54 pp |
| Q4 2017 | 2017-12-31 | 40.55% | −27.61 pp |
| Q3 2017 | 2017-09-30 | 49.63% | −7.60 pp |
| Q2 2017 | 2017-06-30 | 59.50% | −4.96 pp |
| Q1 2017 | 2017-03-31 | 64.96% | +2.87 pp |
| Q4 2016 | 2016-12-31 | 68.16% | −0.24 pp |
| Q3 2016 | 2016-09-30 | 57.23% | — |
| Q2 2016 | 2016-06-30 | 64.47% | — |
| Q1 2016 | 2016-03-31 | 62.09% | — |
| Q3 2015 | 2015-09-30 | 68.40% | — |
Over the last five reported fiscal years, Fulgent Genetics's gross margin decreased from 78.70% to 40.56%, a change of −38.14 percentage points. The latest reported quarter, Q2 2026, shows 30.07%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fulgent Genetics filings at SEC.gov ↗